This site is intended for health professionals only

A stock photo of a Hospice nurse helping an elderly man with Parkinson's Disease and Cancer. The man is receiving palliative hospice care at home.
Published on 9 November 2009

Share this story:

Cetuximab “boosts cancer survival”

teaser

Survival in patients with advanced head and neck cancer is prolonged by adding cetuximab to radiation therapy, according to a report published online first in The Lancet Oncology.

It concludes that as improvement persists for up to five years, it should now be considered as a standard treatment option.

The report notes that most head and neck cancers express the epidermal growth factor receptor (EGFR), and that cetuximab is a monoclonal antibody that specifically targets EGFR.

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

Trials show that patients treated with cetuximab had a 13% improvement in disease control and 10% in survival at three years without increased side effects.

Overall, findings showed an improvement in absolute survival of about 9% in patients given cetuximab compared with those given radiotherapy alone (36.4% vs 45.6%) at five years.

The report says: “Future studies will be designed to help provide a pathway to individualised patient treatments. The analysis of molecular markers … will help refine our ability to select the patients who will benefit from the various systemic treatments to radiotherapy.”

Copyright © Press Association 2009

The Lancet Oncology






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x